Lung perfusion and other methods of targeting therapy to lung tumors.
As therapies for cancer and other diseases continue to evolve on a molecular and genetic basis, delivering these sophisticated agents will continue to be problematic. Although the agents may be highly effective in the laboratory, their true worth can only be measured by clinical responses. In certain instances, the skills of a thoracic surgeon may be called upon to provide the means of delivering therapy rather than to perform therapy, as is our custom. The techniques discussed in this review are just a few of the many possibilities for targeting agents in an effort to enhance their clinical efficacy.
Johnston
M R
MR
Division of Thoracic Surgery, University of Toronto Faculty of Medicine, Canada.
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity; D004333:Drug Administration Routes; D006801:Humans; D006979:Hyperthermia, Induced; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008168:Lung / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy; D051381:Rats; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013552:Swine; D013556:Swine, Miniature; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin